|
|
|
| Analysis on the clinical characteristics and prognosis of elderly patients with high-grade glioma |
| ZHONG Jiangfen LAI Mingyao CAI Linbo▲ |
| Department of Oncology, Guangdong Sanjiu Brain Hospital, Guangdong Province, Guangzhou 510510, China |
|
|
|
Abstract Objective To summarize the clinical features, prognostic factors, and treatment patterns of elderly high-grade gliomas. Methods The clinical data of 84 elderly patients with high-grade glioma (≥65 years old) diagnosed in Guangdong Sanjiu Brain Hospital from January 2008 to January 2021 were collected, and the clinical characteristics and prognostic factors were analyzed. Results Postoperative Karnofsky performance status (KPS) score, histological type, O6-methylguanine-DNA methyltransferase (MGMT) status, surgical method, postoperative treatment mode, whether to maintain chemotherapy, and the number of maintenance chemotherapy cycles were related factors affecting overall survival (P ＜ 0.05). Preoperative KPS score was not related to the completion of radiotherapy (P ＞ 0.05); postoperative KPS score was related to the completion of radiotherapy (P ＜ 0.05). Multivariate Cox regression model showed that negative MGMT immunohistochemistry and ≥six cycles of maintenance chemotherapy were prognostic factors (P ＜ 0.05). Conclusion For elderly high-grade gliomas, the maximum range of safe resection has a survival benefit. It is recommended to perform comprehensive treatment with active radiotherapy after surgery. However, the optimal separation method still needs to be further explored. Negative MGMT immunohistochemistry can benefit from temozolomide treatment, and long-term maintenance chemotherapy can further prolong survival.
|
|
|
|
|
|
[1] Ostrom QT，Gittleman H，Truitt G，et al. CBTRUS Statistical Report：Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015 [J]. Neuro-Oncology，2018，20（10 SUPPL）：iv1-iv86.
[2] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南（2015）.[J].中华医学杂志，2016（7）：485-509.
[3] Laigle-Donadey F. Glioblastoma in the elderly [J]. Geriatr Psychol Neuropsychiatr Vieil，2019，17（2）：173-178.
[4] Louis DN，Perry A，Reifenberger G，et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary [J]. Acta Neuropathologica，2016，131（6）：803-820.
[5] Lorimer CF，Hanna C，Saran F，et al. Challenges to Treating Older Glioblastoma Patients：the Influence of Clinical and Tumour Characteristics on Survival Outcomes [J]. Clin Oncol，2017，29（11）：739-747.
[6] 王雅宁，王月坤，孔梓任，等.老年高级别胶质瘤的临床特点和治疗[J].中华神经外科杂志，2020，36（2）：146-150.
[7] 陈怡东，邱晓光.2018年脑胶质瘤放化疗进展[J].中华医学信息导报，2019，34（1）：14.
[8] Brodbelt A，Greenberg D，Winters T，et al. Glioblastoma in England：2007-2011 [J]. Eur J Cancer，2015，51（4）：533-542.
[9] 刘竞辉，王樑，娄淼，等.老年胶质瘤预后相关因素分析[J].中南大学学报（医学版），2018，43（4）：403-409.
[10] Okada M，Miyake K，Tamiya T. Glioblastoma Treatment in the Elderly [J]. Neurol Med Chir （Tokyo），2017，57（12）：667-676.
[11] 陈立久，颜伟，李文涛，等.胶质母细胞瘤手术切除程度与患者生存预后的相关性分析[J].国际神经病学神经外科学杂志，2019，46（2）：154-158.
[12] 蒋海辉，林松.脑胶质母细胞瘤的治疗现状与展望[J].中华外科杂志，2020，58（1）：70-74.
[13] 马文斌，王裕，王樑，等.中国老年胶质瘤患者术前评估专家共识（2019）[J].协和医学杂志，2019，10（4）：326-335.
[14] Conti Nibali M，Gay LG，Sciortino T，et al. Surgery for Glioblastoma in Elderly Patients [J]. Neurosurg Clin N Am，2021，32（1）：137-148.
[15] Keime-Guibert F，Chinot O，Taillandier L，et al. Radiotherapy for glioblastoma in the elderly [J]. N Engl J Med，2007，356（15）：1527-1535.
[16] 陈正和，陈忠平.高级别胶质瘤的治疗现状及思考[J].中国临床神经外科杂志，2016，21（6）：350-352.
[17] 中华医学会放射肿瘤治疗学分会.胶质瘤放疗中国专家共识（2017）[J].中华放射肿瘤学杂志，2018，27（2）：123-131.
[18] Roth P，Gramatzki D，Weller M. Management of Elderly Patients with Glioblastoma [J]. Curr Neurol Neurosci Rep，2017，17（4）：35.
[29] Saeed H，Tseng YD，Lo SS. Narrative review of palliative hypofractionated radiotherapy for high grade glioma [J]. Ann Palliat Med，2021，10（1）：846-862.
[20] Perry JR，Laperriere N，O’Callaghan CJ，et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma [J]. N Engl J Med，2017，376（11）：1027-1037.
[21] 白洁，张全华，高凌宜，等.替莫唑胺联合贝伐单抗治疗老年患者恶性脑胶质瘤的临床疗效分析[J].西北国防医学杂志，2017，38（8）：522-524.
[22] Kalra B，Kannan S，Gupta T. Optimal adjuvant therapy in elderly glioblastoma：results from a systematic review and network meta-analysis [J]. J Neurooncol，2020，146（2）：311-320.
[23] Han S，Liu Y，Cai SJ，et al. IDH mutation in glioma：molecular mechanisms and potential therapeutic targets [J]. Br J Cancer，2020，122（11）：1580-1589.
[24] 杨钰桢，郝解贺，万大海.老年多形性胶质母细胞瘤的治疗进展.[J].山东医药，2019，59（16）：89-93.
[25] 孙亚方，王政，石祥宇，等.老年胶质母细胞瘤患者MGMT甲基化状态对放化疗及预后影响.[J].中华放射肿瘤学杂志，2021，30（5）：446-450. |
|
|
|
